A Translational Phase 1B, 2-Part Study to Evaluate Pharmacokinetics, Safety and Pharmacodynamics of Treatment with ATX-304 Na Salt Tablets.

2023-505967-36-00 Human pharmacology (Phase I) - Other Ended

Start 15 Sep 2023 · End 7 May 2025 · Status Ended · 2 EU/EEA countries · 2 sites

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 72
Countries 2
Sites 2

Obesity with prediabetes or type 2 diabetes mellitus

Key facts

Sponsor
Betagenon AB
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
15 Sep 2023 → 7 May 2025
Decision date (initial)
2024-03-19
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Obesity with prediabetes or type 2 diabetes mellitus

VersionLevelCodeTermSystem organ class
23.0 LLT 10082306 Cardiometabolic syndrome 10027433

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Betagenon AB

Sponsor organisation
Betagenon AB
Address
Vastra Strandgatan 9b, Umea Stadsfors Umea Stadsfors
City
Umea
Postcode
903 26
Country
Sweden

Scientific contact point

Organisation
Betagenon AB
Contact name
Vice President Clinical Development

Public contact point

Organisation
Betagenon AB
Contact name
Vice President Clinical Development

Locations

2 EU/EEA countries · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 24 1
Netherlands Ended 48 1
Rest of world 0

Investigational sites

Germany

1 site · Ended
PROFIL Institut fuer Stoffwechselforschung GmbH
n/a, Hellersbergstrasse 9, Hammfeld, Neuss

Netherlands

1 site · Ended
QPS Netherlands B.V.
Clinical Pharmacology, Hanzeplein 1, 9713 GZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-03-28 2025-05-07 2024-03-28 2025-05-07
Netherlands 2023-09-15 2023-12-05 2023-09-20

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-07 Netherlands Acceptable
2023-09-15
2023-09-15
2 NON SUBSTANTIAL MODIFICATION NSM-4 2023-12-13 Netherlands Acceptable
2023-09-15
2023-12-13
3 SUBSEQUENT ADDITION OF MSC APP-3 2023-12-19 Acceptable
2023-09-15
2024-03-19
4 NON SUBSTANTIAL MODIFICATION NSM-5 2024-03-27 Netherlands Acceptable
2023-09-15
2024-03-27
5 SUBSTANTIAL MODIFICATION SM-2 2024-05-17 Netherlands Acceptable
2024-08-15
2024-08-15
6 SUBSTANTIAL MODIFICATION SM-3 2024-08-23 Acceptable
2024-10-14
2024-10-16